The Role of Raman Spectroscopy Within Quantitative Metabolomics.
Cassio Lima, Howbeer Muhamadali, Royston Goodacre
https://pubmed.ncbi.nlm.nih.gov/33826853Actively Recruiting
All Genders
Healthy Volunteers
ID06760845
Research on Raman Spectroscopy Detection Technology in Kidney Disease Diagnosis
Led by Zunsong Wang · Updated on 2025-01-07
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with specific kidney diseases including IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis. The goal is to develop a non-invasive and efficient diagnostic method using Raman spectroscopy combined with statistical analysis. This approach aims to assist in diagnosing these kidney diseases and predicting treatment outcomes based on data collected from renal biopsy-confirmed patients. The study involves collecting serum and morning urine samples from patients, which are then analyzed using Raman spectroscopy to obtain spectral data. The data is processed to identify chemical bonds and quantify analyte concentrations. Statistical methods like principal component analysis and Mahalanobis distance discriminant modeling are used to classify and predict disease types. This is an observational study with no experimental treatment. Participants provide blood and urine samples within two days of enrollment, which are scanned using Raman spectroscopy. Researchers analyze the spectral images to measure chemical substance peaks and concentration levels. The primary outcome is the quality and interpretation of these Raman spectroscopy images. The study runs from February 2021 through July 2025, with all data collection completed within a short time frame after enrollment.
CONDITIONS
Brief Title
Raman Spectroscopy Diagnosis of Kidney Diseases
Who Can Participate
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy
- No prior hormone or immunosuppressive therapy before renal biopsy
You will not qualify if you...
- Secondary membranous nephropathy caused by autoimmune diseases, infections, drugs, or toxins
- Severe infections with elevated white blood cell count and symptoms like fever, cough, or skin infections
- Severe cardiovascular diseases including chronic heart failure grade 3 or above and arrhythmias
- Active infectious diseases such as hepatitis, AIDS, or syphilis
- Diagnosed tumors or signs indicating possible tumors
- Incomplete data or missed diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Within 2 days from enrollment
Participants undergo Raman spectroscopy imaging of blood and urine for kidney disease diagnosis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Shandong Second Medical University. No.7166 Baotong West Street, Weifang, Shandong, 261053, China.
Jinan, Shandong, China, 250000
Actively Recruiting
Loading map...
Research Team
Z
Zunsong Wang, Dr
M
Mengyu Wu, Dr
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here